SCA
PTLA

Spearhead Capital Advisors’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Spearhead Capital Advisors’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-18,359
Closed -$330K – 189
2020
Q2 		$330K Buy
18,359
+4,906
+36% +$68.2K 0.07% 93
2020
Q1 		$96K Buy
+13,453
New +$168K 0.03% 102

Spearhead Capital Advisors's PTLA Position: Q3 2020 in Review

Spearhead Capital Advisors sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 18,359 shares — an estimated $330K sold.

Spearhead Capital Advisors first reported a position in PTLA in Q1 2020 and held it in 2 quarters. The position peaked at $330K in Q2 2020. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

  • Spearhead Capital Advisors reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
  • Spearhead Capital Advisors sold 18,359 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $330K.
  • Spearhead Capital Advisors first reported a position in Portola Pharmaceuticals, Inc. in Q1 2020 and held it in 2 quarters.
  • Spearhead Capital Advisors's Portola Pharmaceuticals, Inc. position peaked at $330K in Q2 2020.
  • 0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on Spearhead Capital Advisors's 13F filing for Q3 2020, filed 16 Oct 2020.